car-t targeted cd19/cd20/cd22/cd30
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02782351)
Timeline
Indications
Mechanism of action
- Tumor necrosis factor receptor superfamily member 8Immunity, passive
TNFRSF8 immunity, passive
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- car-t targeted cd19/cd20/cd22/cd30
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03196830 | Phase 2 | Jun 1, 2017 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, Soochow University |
| NCT02782351 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | iCarTAB BioMed Inc., Xuzhou Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| iCarTAB BioMed Inc. | For profit | 1 | 0 | 1 | 2016 |
| Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | For profit | 1 | 0 | 1 | 2017 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Xuzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1